NASDAQ:QNCX
Quince Therapeutics, Inc. Stock News
$0.650
-0.0300 (-4.41%)
At Close: Jun 20, 2024
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
07:00am, Monday, 03'rd Jun 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to lever
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
07:00am, Monday, 13'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to lever
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
04:05pm, Monday, 06'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to lever
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
05:51pm, Thursday, 07'th Mar 2024
Two microcap biotech stocks to consider for the science-challenged among us.
Quince Therapeutics Launches Scientific Advisory Board
07:00am, Thursday, 22'nd Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
07:00am, Thursday, 15'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
04:05pm, Wednesday, 07'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics to Participate at Investor Events in January 2024
04:05pm, Thursday, 04'th Jan 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
07:00am, Monday, 23'rd Oct 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
04:05pm, Thursday, 28'th Sep 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
07:00am, Wednesday, 06'th Sep 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
04:05pm, Thursday, 10'th Aug 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.
08:00am, Thursday, 13'th Jul 2023
Offers $1.80 per share in cash plus CVR to receive 85% of the future net proceeds Quince receives as part of the Lighthouse Pharmaceuticals transaction Stock trades below its net cash and investments
The Anatomy of Penny Stocks: Understanding What Drives Value
06:00am, Wednesday, 22'nd Mar 2023
Here's how to understand what components drive value with penny stocks The post The Anatomy of Penny Stocks: Understanding What Drives Value appeared first on Penny Stocks to Buy, Picks, News and Info
